Biochempeg Scientific Inc. developed a series of PEG compounds  used for Semaglutide

By: Biochempeg
WATERTOWN, Mass. - April 26, 2020 - PRLog -- Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. Biochempeg has developed and can supply some key intermediates of Semaglutide.

Semaglutide (trade names Rybelsus, Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. It was given a brand name Ozempic. Clinical trials were started in 2015, and phase 3 was completed in 2016. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) so that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient.

Biochempeg supplies some key intermediates of Semaglutide with high quality & fast shipping. There are 4 kinds of key intermediates of Semaglutide for your research.


CatalogID: 10821 Purity: ≥95% CAS NO.: 166108-71-0

Price: $500/100g


CatalogID: 10803 Purity: ≥95% CAS NO.: 134978-97-5

Price: $180/1g  $600/5g


CatalogID: 10852 Purity: ≥95% CAS NO.: 108466-89-3

Price: $380/5g  $600/10g


CatalogID: 12311 Purity: ≥95% CAS NO.: 134979-01-4

Price: inquiry

Company: Biochempeg Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA

Sonia Lee
Posted By:*** Email Verified
Location:Watertown - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share